Abstract:Epstein–Barr virus (EBV) infection is a global health concern infecting over 90% of the population. However, there is no currently available vaccine. EBV primarily infects B cells, where the major glycoprotein 350 (gp350) is the main target of neutralizing antibodies. Given the advancement of nanoparticle vaccines, we describe rationally designed vaccine modalities presenting 60 copies of gp350 on self-assembled nanoparticles in a repetitive array. In a mouse model, gp350s on lumazine synthase (LS) and I3-01 adjuvanted with MF59 or aluminum hydroxide (Alhydrogel) elicited over 65- to 133-fold higher neutralizing antibody titers than the corresponding gp350 monomer to EBV. Furthermore, immunization with gp350D123-LS and gp350D123-I3-01 vaccine induced a Th2-biased response. For the nonhuman primate model, gp350D123-LS in MF59 elicited higher titers of total IgG and neutralizing antibodies than the monomeric gp350D123. Overall, these results support gp350D123-based nanoparticle vaccine design as a promising vaccine candidate for potent protection against EBV infection.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c04687?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c04687</a>.Materials and methods; kinetic analysis and biophysical characteristics of gp350-based nanoparticles; neutralizing antibodies induced by the gp350-based nanoparticle formulated with aluminum hydroxide adjuvant in mice; serum IgA, IgM, and IgG subclass profiles; durability of the immune response of gp350-based vaccines; characteristics of six cynomolgus macaques in immunization studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c04687/suppl_file/nl0c04687_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Development of a Robust, Higher Throughput Green Fluorescent Protein (Gfp)-Based Epstein-Barr Virus (EBV) Micro-Neutralization Assay.

A Novel High Throughput Assay to Quantify Epstein-Barr Virus Neutralizing Antibody Activity Against B-cell and Epithelial Cell Infections for Vaccine and Therapeutic Developments.

A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice

Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection

A Frontier in EBV Vaccine Research: mRNA-Based Immunization with gp350, gp42, and gL Glycoproteins

A Novel Vaccine Candidate Based on Chimeric Virus-Like Particle Displaying Multiple Conserved Epitope Peptides Induced Neutralizing Antibodies Against EBV Infection

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV

An Insect Cell-Derived Extracellular Vesicle-Based Gb Vaccine Elicits Robust Adaptive Immune Responses Against Epstein-Barr Virus

Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

Lytic Replication and Inductive Production of Recombinant Epstein Barr Virus Visualized

Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity

Generation Of Recombinant Rabies Virus Cvs-11 Expressing Egfp Applied To The Rapid Virus Neutralization Test

Multiple cross displacement amplification combined with nanoparticle-based lateral flow biosensor for rapid and sensitive detection of Epstein-Barr virus

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.

Development of a Rapid Epstein–Barr Virus Detection System Based on Recombinase Polymerase Amplification and a Lateral Flow Assay

A Cocktail Nanovaccine Targeting Key Entry Glycoproteins Elicits High Neutralizing Antibody Levels Against EBV Infection

An Expeditious Neutralization Assay for Porcine Reproductive and Respiratory Syndrome Virus Based on a Recombinant Virus Expressing Green Fluorescent Protein

Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use

Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region

Development of a novel method for detection of rabies virus neutralizing antibody